Yaoshibang, a Guangzhou-based business-to-business (B2B) pharmaceutical trading platform, announced that it has completed a US$133 million new round of financing from Tiger Global Management, DCM Ventures and China’s H Capital.
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Read 2 Articles for Free with a Basic Account
Gain limited and restricted access to China Money Network.
Register Basic AccountSubscribe for an annual subscription!
Enjoy comprehensive and exclusive data you can't find elsewhere!
More Info
Already have an account or paid subscription? Log in
